Entera Bio Ltd. (NASDAQ:ENTX) Q3 2019 Earnings Conference Call November 21, 2019 8:30 AM ET
Company Participants
Adam Gridley - Chief Executive Officer
Phillip Schwartz - President of R&D
Arth Santora - Chief Medical Officer
Dana Yaacov-Garbeli - Interim Chief Financial Officer
Conference Call Participants
Joanne Lee - Maxim Group
Operator
Good morning. My name is Sonia, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Entera Bio Third Quarter 2019 Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-an-answer session.
Adam Gridley, you may begin the conference call.
Adam Gridley
Good morning. Thank you and we welcome you to the call. Joining me today on the call are; Philip Schwartz, our President of R&D; Arth Santora, our Chief Medical Officer; and Dana Yaacov-Garbeli, our Interim CFO.
A press release announcing Entera's financial and operating results for the third quarter of 2019 was issued this morning. For those of you who have not yet seen it, you'll find it posted in the Investor section of our website at www.enterabio.com, and it is also available at the SEC's website. On our call this morning, we will share with you a business update and our financial results, which will be followed by question-and-answer session.
During today's call, we will be making forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These include statements that address future operating, financial, or business performance or our strategies or expectations.
Forward-looking statements are based on management's current expectations and belief, and involve significant risks and uncertainties that could cause actual results, developments, and business decisions to differ materially from those contemplated by those statements.
Those risks and uncertainties
- Read more current ENTX analysis and news
- View all earnings call transcripts